Citations

Clear

1407 citation(s) found for "Yu, Chan".

Presentation and outcomes of mitral valve surgery in France in the recent era: a nationwide perspective
Messika–Zeitoun, David , Candolfi, Pascal , Enriquez‐Sarano, Maurice , Burwash, Ian G. , Philippon, Jean-Francois, Toussaint, Jean-Manuel, Verta, Partrick, Feldman, Ted , Iung, Bernard , Glineur, David , Vahanian, Alec , Mesana, Thierry, Enriquez-Sarano, Maurice , Messika-Zeitoun, David , Chan, Vincent , Philippon, Jean-François, Toussaint, Jean-Manuel, Obadia, Jean‐François

Mayo Clinic

Open Heart | August 12, 2020 | Volume: 7 | Issue: 2 | Pages: e001339

10.1136/openhrt-2020-001339 | PMID 32788294 Get It

Objectives Unbiased information regarding the surgical management of patients with mitral regurgitation (MR) at the nationwide level are scarce and mainly US-based. The Programme de Médicalisation des Systèmes d’Information, a mandatory national database, offers the unique opportunity to assess the presentation and outcomes of all consecutive mitral valve (MV) surgeries performed in France in the contemporary era. Methods We collected all MV surgeries performed for MR in France in 2014–2016. MR aetiology was classified as degenerative (DMR), secondary (SMR) or Other (rheumatic or congenital disease and infective endocarditis). Results During the 3-year period, 18 167 MV surgeries were performed in France (55% repair and 45% replacement; 52% isolated). Age was 66±12 years and 59% were male. Aetiology was DMR in 42%, SMR in 16% and other in 42% including 19% with uncertain aetiologies. Overall, in-hospital mortality was 6.5% and increased with age, female gender, Charlson Comorbidity Index, type of surgery (replacement vs repair), associated surgery (combined vs isolated) and MR aetiology (all p<0.01). In-hospital mortality and rate of death/readmission for heart failure (HF) at 1 year were 3.4% and 13%, respectively for DMR (2.4% and 11% for isolated DMR) and 7.8% and 27%, respectively for SMR (5.5% and 23% for isolated SMR). Repair rate was 55% overall, 68% in DMR and 72% for isolated DMR surgery (70% of all DMR). Repair rates decreased with age, Charlson Comorbidity Index and female sex (all p<0.0001). Conclusion In this cross-sectional contemporary prospective nationwide database, in-hospital mortality and 1 year rate of death and HF readmission were considerable overall and in all subsets. Repair rates were suboptimal overall especially in the elderly and women subsets. These results underline the need to develop strategies to improve management and outcomes of patients with both DMR and SMR.
Practice patterns and recommendations for pediatric image‐guided radiotherapy: A Children's Oncology Group report
Hua, Chia‐Ho , Vern-Gross, T.Z., Olch, Arthur J. , Alaei, Parham , Sathiaseelan, Vythialingam, Ulin, Kenneth, Laurie, Fran, Gopalakrishnan, Mahesh , Krasin, Matthew J. , Merchant, Thomas E. , Donaldson, Sarah S. , FitzGerald, Thomas J. , Haas‐Kogan, Daphne A. , Mahajan, Anita , Marcus, Karen J. , Taylor, Paige A. , Ahern, Verity , Followill, D , Breneman, John C. , Kalapurakal, John A. , Hodgson, David , Vern-Gross, Tamara Z, Wolden, Suzanne , Merchant, Thomas E , Donaldson, Sarah S , FitzGerald, Thomas J , Hodgson, David C , Laack, Nadia N Issa , Krasin, Matthew J , Taylor, Paige , Hodgson, David , Hess, Clayton Burnett , Deng, Jun , Gopalakrishnan, Mahesh, Esiashvili, Natia , Wolden, Suzanne L. , Constine, Louis S , Laack, Nadia N. , Buchsbaum, Jeffrey Craig

Mayo Clinic

Pediatric Blood & Cancer | August 10, 2020 | Volume: 67 | Issue: 10 | Pages: No page available

10.1002/pbc.28629 | PMID 32776500 Get It

AbstractThis report by the Radiation Oncology Discipline of Children's Oncology Group (COG) describes the practice patterns of pediatric image‐guided radiotherapy (IGRT) based on a member survey and provides practice recommendations accordingly. The survey comprised of 11 vignettes asking clinicians about their recommended treatment modalities, IGRT preferences, and frequency of in‐room verification. Technical questions asked physicists about imaging protocols, dose reduction, setup correction, and adaptive therapy. In this report, the COG Radiation Oncology Discipline provides an IGRT modality/frequency decision tree and the expert guidelines for the practice of ionizing image guidance in pediatric radiotherapy patients.
O-003 Results of the stroke thromboembolism registry of imaging and pathology: a multicenter international study
Brinjikji, Waleed , Hanel, R, Delgado, J, Gounis, Matthew J. , Doyle, Karen , Kvamme, Peter , Kadirvel, Ramanathan , Kallmes, David F. , Nogueira, Raul G. , Hanel, Ricardó A. , Layton, Kennith F. , Delgado, J, Yoo, Albert J. , Mendes Pereira, Vitor , Almekhlafi, Mohammed , Patel, Biraj M. , Jahromi, Babak S. , Dai, Daying , Fitzgerald, Seán

Mayo Clinic

Oral Abstracts | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2.1-A2

10.1136/neurintsurg-2020-snis.3 Get It

E-212 Pulserider in the treatment of wide-neck bifurcation aneurysms: interim results of the NAPA trial
Spiotta, Alejandro M , Ebersole, Koji , Lena, Jonathan , Starke, Robert M. , Puri, A, Yavagal, Dileep R. , Bohnstedt, Bradley N. , Rangel-Castilla, Leonardo , Cheema, Ali, Rodrigues, K de Macedo , Grossberg, Jonathan A , Leacy, Reade De , Rangel-Castilla, Leonardo , Cheema, A, Davies, Jason M. , Howard, Brian M , Kellner, Christopher Paul , Lanzino, Giuseppe , Tateshima, Satoshi

Mayo Clinic

Electronic Poster Abstracts | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: A144.2-A145

10.1136/neurintsurg-2020-snis.243 Get It

Trends in Emergency Department Visits and Hospital Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic in the US
Jeffery, Molly M. , D’Onofrio, Gail , Paek, Hyung , Platts‐Mills, Timothy F. , Soares, William E. , Hoppe, Jason , Genes, Nicholas , Nath, Bidisha , Melnick, Edward R. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

JAMA Internal Medicine | August 3, 2020 | Volume: 180 | Issue: 10 | Pages: 1328

10.1001/jamainternmed.2020.3288 | PMID 32744612 Get It

Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
Scholand, Mary Beth , Lynch, David A. , Colby, Thomas V. , Groshong, Steve D. , Benzaquen, Sadia , Nathan, Steven D. , Davis, John R., Schmidt, Shelley L., Hagmeyer, Lars , Sonetti, David A., Hetzel, Jürgen, Case, Amy Hajari , Ramaswamy, Murali, Calero, Karel , Gauhar, Umair, Lancaster, Lisa , Choi, Yoonha, Pankratz, Daniel G., Walsh, P. Sean, Lofaro, Lori , Huang, Jing , Bhorade, Sangeeta , Kennedy, Giulia C., Raghu, Ganesh , Richeldi, Luca , Myers, Jeffrey L. , Chung, Jonathan Hero , Davis, J. Russell, Criner, Gerard J. , Patel, Nina , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 28, 2020 | Volume: 203 | Issue: 2 | Pages: 211-220

10.1164/rccm.202003-0877oc | PMID 32721166 Get It

Abstract Rationale Usual interstitial pneumonia (UIP) is the defining morphology of idiopathic pulmonary fibrosis (IPF). Guidelines for IPF diagnosis conditionally recommend surgical lung biopsy for histopathology diagnosis of UIP when radiology and clinical context are not definitive. A “molecular diagnosis of UIP” in transbronchial lung biopsy, the Envisia Genomic Classifier, accurately predicted histopathologic UIP. Objectives We evaluated the combined accuracy of the Envisia Genomic Classifier and local radiology in the detection of UIP pattern. Methods Ninety-six patients who had diagnostic lung pathology as well as a transbronchial lung biopsy for molecular testing with Envisia Genomic Classifier were included in this analysis. The classifier results were scored against reference pathology. UIP identified on high-resolution computed tomography (HRCT) as documented by features in local radiologists’ reports was compared with histopathology. Measurements and Main Results In 96 patients, the Envisia Classifier achieved a specificity of 92.1% (confidence interval [CI],78.6–98.3%) and a sensitivity of 60.3% (CI, 46.6–73.0%) for histology-proven UIP pattern. Local radiologists identified UIP in 18 of 53 patients with UIP histopathology, with a sensitivity of 34.0% (CI, 21.5–48.3%) and a specificity of 96.9% (CI, 83.8–100%). In conjunction with HRCT patterns of UIP, the Envisia Classifier results identified 24 additional patients with UIP (sensitivity 79.2%; specificity 90.6%). Conclusions In 96 patients with suspected interstitial lung disease, the Envisia Genomic Classifier identified UIP regardless of HRCT pattern. These results suggest that recognition of a UIP pattern by the Envisia Genomic Classifier combined with HRCT and clinical factors in a multidisciplinary discussion may assist clinicians in making an interstitial lung disease (especially IPF) diagnosis without the need for a surgical lung biopsy.
Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
Chan, Onyee , Kerr, Daniel, Idrees, Afshan, Sweet, Kendra , Kharfan‐Dabaja, Mohamed A. , Sokol, Lubomir , Chan, Onyee , Yun, Seongseok , Vincelette, Nicole D. , Mo, Qianxing , Lancet, Jeffrey E. , Zhang, Ling , Sokol, Lubomir

Mayo Clinic

Blood Advances | July 28, 2020 | Volume: 4 | Issue: 14 | Pages: 3435-3442

10.1182/bloodadvances.2020001875 | PMID 32722779 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with dismal clinical outcomes. Conventional chemotherapies such cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose cytarabine and methotrexate (CVAD) have been commonly used for the BPDCN treatment until a recent study showed promising outcomes in patients treated with SL-401 (Tagraxofusp). In this single-institution retrospective study, we identified a total of 49 consecutive BPDCN patients. Among 42 patients who received treatment, hyper-CVAD regimen was associated with higher complete response rate compared with CHOP-based regimens or SL-401 (91% vs 50% vs 50%), although the difference did not achieve statistical significance. Furthermore, there was no significant overall survival (OS) difference between patients treated with SL-401 vs other chemotherapies as their first-line treatment (hazard ratio = 1.597; 95% CI, 0.460-5.548; P = .431). Of note, patients who received allogeneic stem cell transplant (allo-SCT) had significantly longer OS (hazard ratio = 0.160; 95% CI, 0.0453-0.56; P = .041). Extent of disease (skin vs bone marrow vs both) or younger age (&lt;60 years old) did not have significant prognostic impact on OS. Collectively, our study confirmed the survival benefit of allo-SCT and suggests that conventional and intensive chemotherapies such as CHOP and hyper-CVAD as well as SL-401 would be comparable first-line choice for the BPDCN patients.
In Reply: A Comparison of Minimally Invasive and Open Transforaminal Lumbar Interbody Fusion for Grade 1 Degenerative Lumbar Spondylolisthesis: An Analysis of the Prospective Quality Outcomes Database
Chan, Andrew K. , Bission, Erica F, Bydon, Mohamad , Mummaneni, Praveen V.

Mayo Clinic

Neurosurgery | July 24, 2020 | Volume: 87 | Issue: 5 | Pages: E609-E610

10.1093/neuros/nyaa372 | PMID 32814967 Get It

Dismal Outcomes and High Societal Burden of Mitral Valve Regurgitation in France in the Recent Era: A Nationwide Perspective
Messika–Zeitoun, David , Candolfi, Pascal , Vahanian, Alec , Burwash, Ian G. , Philippon, Jean-François, Toussaint, Jean-Manuel, Verta, Patrick, Feldman, Ted , Iung, Bernard , Glineur, David , Mesana, Thierry, Enriquez‐Sarano, Maurice , Enriquez-Sarano, Maurice , Messika-Zeitoun, David , Chan, Vincent

Mayo Clinic

Journal of the American Heart Association | July 22, 2020 | Volume: 9 | Issue: 15 | Pages: No page available

10.1161/jaha.120.016086 | PMID 32696692 Get It

Background Although US recent data suggest that mitral regurgitation (MR) is severely undertreated and carries a poor outcome, population‐based views on outcome and management are limited. We aimed to define the current treatment standards, clinical outcomes, and costs related to MR at the nationwide level. Methods and Results In total, 107 412 patients with MR were admitted in France in 2014 to 2015. Within 1 year, 8% were operated and 92% were conservatively managed and constituted our study population (68% primary MR and 32% secondary MR). The mean age was 77±15 years; most patients presented with comorbidities. In‐hospital and 1‐year mortality rates were 4.1% and 14.3%, respectively. Readmissions were common (63% at least once and 37% readmitted ≥2 times). Rates of 1‐year mortality or all‐cause readmission and 1‐year mortality or heart failure readmission were 67% and 34%, respectively, and increased with age, Charlson index, heart failure at admission, and secondary MR etiology; however, the event rate remained notably high in the primary MR subset (64% and 28%, respectively). The mean costs of hospital admissions and of readmissions were 5345±6432 and 10 080±10 847 euros, respectively. Conclusions At the nationwide level, MR was a common reason for admission and affected an elderly population with frequent comorbidities. Less than 10% of patients underwent a valve intervention. All subsets of patients who were conservatively managed incurred high mortality and readmissions rates, and MR represented a major societal burden with an extrapolated annual cost of 350 to 550 million euros (390–615 million US dollars). New strategies to improve the management and outcomes of patients with both primary and secondary MR are critical and warranted.